鹽野義製藥：製藥企業分析報告書 是由出版商Espicom Business Intelligence在2010年03月所出版的。
這份英文市場調查報告書包含Pages: 84 價格從美金1040起跳。
Abstract
Shionogi operates in a number of business fields, and principal among these is
its Pharmaceuticals segment. Within this business segment, Shionogi is active
in the following therapeutic areas: Infectious Diseases, Metabolic Syndrome,
Anticancer, Neurology, Allergy and Circulatory. As part of Shionogi,s Second
Medium-Term Management Plan (which began in April 2005, and runs until fiscal
2010), the company is planning to focus research efforts specifically on the
treatment of infections, pain and metabolic syndrome.
Within Japan, Shionogi is recognised as one of the leading antibiotics
companies and in recent years, Flomox, Flumarin and Vancomycin have all
maintained their positions as top sellers in their product categories.
However, a contracting antibiotic market and increased competition have
impacted negatively on sales. To address this issue Shionogi has developed and
launched Finibax (September 2005), and licensed-in Bayer,s Avelox (launched in
Japan in December 2005). The company has also revitalised its metabolic
syndrome product range with the launches of Crestor and Irbetan, both of which
are expected to vie for the position of Shionogi' s top-selling product within
our forecast period.
To ensure long-term growth, Shionogi has succeeded in developing an
encouraging pipeline containing several promising candidate drugs, most
notably duloxetine. As one of the smaller pharmaceutical companies in Japan,
this has largely been achieved through in-licensing. Shionogi is concentrating
resources in the three target areas of infection, pain and metabolic syndrome,
with the aim of advancing at least five new chemical compounds to Phase II or
more advanced stages by the end of fiscal 2009.
Shionogi has a limited global profile, but has achieved substantial success
from out-licensing major products in overseas markets to maximise their sales
values and utilise the marketing infrastructures of overseas companies. The US
development of Finibax was conducted by Peninsula Pharmaceuticals (now
acquired by Johnson & Johnson) and the product was launched during 2007.
Shionogi now has the possibility of overseas expansion in the antibiotics
field.
This new strategic analysis report Shionogi: Pipeline - Products -
Performance - Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts of key
products. Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Performance
- Geographic Performance
- Company Strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions
- THERAPEUTIC AREA FOCUS
- R&D PIPELIN E
- IN FECTIO US DISEASES
- Marketed Products
- Avelox
- Finibax
- Flomox
- Flumarin
- Peramivir
- Tamiflu
- Vancomycin
- Others
- R&D Projects
- Growth Forecast
- ANTICANCER
- Marketed Products
- R&D Projects
- Growth Forecast
- ALLERGY
- Marketed Products
- R&D Projects
- S-444823
- S-555739
- S-777469
- Growth Forecast
- METABOLIC SYNDROME
- Marketed Products
- R&D Projects
- S-0139
- S-234462
- S-888711
- Velneperit
- Growth Forecast
- NEUROLOG Y
- Marketed Products
- Cymbalta
- OxyContin
- Others
- R&D Projects
- Growth Forecast
- OTHER
- Marketed Products
- Cetrotide
- Differin
- Others
- R&D Projects
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Anthera Pharmaceuticals Inc.
- AstraZeneca
- Bayer
- BioCryst Pharmaceuticals Inc.
- Bristol-Myers Squibb
- Eli Lilly
- Enanta Pharmaceuticals Inc.
- Galderma KK
- GlaxoSmithKline
- Johnson & Johnson
- Marnac Inc/KDL Inc.
- Merck & Co
- MorphoSys AG
- MundiPharma BV
- Napp Pharmaceuticals Ltd.
- OncoTherapy Science Inc (OTS)
- Plethora Solutions Holdings Ltd.
- Purdue Pharma LP
- Quark Biotech Inc (QBI)
- Roche
- sanofi-aventis
- APPENDIX 4 - INFRASTRUCTURE
- Research And Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - MAJOR PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint-venture Companies
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Capital Expenditure By Business Area
- Sales By Business Area
- Operating Income By Business Area
- Total Assets By Business Area
- Overseas Sales By Region
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Infectious Diseases Products, 2009
- Major Anticancer Products, 2009
- Major Allergy Products, 2008
- Major Metabolic Syndrome Products, 2009
- Major Neurology Products, 2009
INDEX OF CHARTS
- Sales, Costs and Operating Income
- R&D Expenditure and Capital Expenditure
- Operating Income By Business Area
- Overseas Sales By Region, 2009
- Sales of Top 10 Products (2003A-2013E)
- Sales of Top Ten Products, 2009
- Avelox Sales (2003A-2013E)
- Finibax Sales (2003A-2013E)
- Flomox Sales (2003A-2013E)
- Flumarin Sales (2003A-2013E)
- Vancomycin Sales (2003A-2013E)
- Imunace Sales (2003A-2013E)
- Claritin Sales (2003A-2013E)
- Pirfenidone Sales (2009E-2013E)
- Crestor Sales (2003A-2013E)
- Irbesartan Sales (2009E-2013E)
- Duloxetine Sales (2009E-2013E)
- OxyContin Sales (2003A-2013E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
